RSS   Newsletter   Contact   Advertise with us
Post Online Media

Ultragenyx Pharmaceutical appoints Shehnaaz Suliman to board

Share on Twitter Share on LinkedIn
Staff Writer | Novato, Ca., USA | Tuesday February 5, 2019 6:23AM ET
Shehnaaz SulimanUltragenyx Pharmaceutical, a biopharmaceutical company, announced the appointment of Shehnaaz Suliman to the company’s board of directors.
Please disable your ad blocker for POST to be able to enjoy our free content.
Dr. Suliman, Senior Vice President of Corporate Development and Strategy of Theravance Biopharma, Inc., will serve as an independent director to Ultragenyx.

Dr. Suliman has held her current position at Theravance since July 2017.

Previously, she worked for Genentech, Inc., as Group Leader and Project Team Leader in the R&D Portfolio Management and Operations Group from September 2010 to May 2015 and then as Vice President and Global Therapeutic Head, Roche Partnering from June 2015 to July 2017.

Prior to Genentech, she held various management roles of increasing responsibility at Gilead Sciences, Inc. between January 2005 and September 2010.

Prior to Gilead, she was an investment banker with Lehman Brothers and Petkevich & Partners, advising public and private companies on buy- and sell-side transactions.

Dr. Suliman is a member of the board of directors of Parvus Therapeutics, Inc., a private biopharmaceutical company.

Dr. Suliman received her M.D. at the University of Cape Town Medical School, South Africa, and holds an M.B.A, with distinction, and M.Phil. in Development Studies degrees from Oxford University, where she was a Rhodes Scholar.



POST Online Media Contact

 More inside POST